The effectiveness of Mexidol Correction in the correction of the post -shoe syndrome in patients with chronic cerebrovascular diseases

Authors:

E.B. Kuznetsova, E.A. Salina, N.S. Kuznetsov

FSBEI in "Saratov State Medical University named after V.I. Razumovsky "Ministry of Health of Russia, Saratov, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 5

Summary:
Purpose of the study. To evaluate the effectiveness of consistent therapy with Mexidol and Mexidol Fort 250 in the correction of post -shoe syndrome (PKS) in patients with chronic cerebrovascular diseases (HCVZ). Material and methods. An analysis of the results of the examination and treatment of 110 patients with the CCVZ who suffered Covid-19 was carried out. Patients of the main group (OG, N = 55) received Mexidol (5 ml of iv in a drip for 14 days with the subsequent transition to the tablet form of Mexidol Fort 250, 1 tablet 3 times a day for 2 months); 55 patients of the comparison group (GS) did not receive antioxidants. All included in the study of patients conducted an MRI examination and detailed neuropsychological testing. Results. Patients have a significant improvement in the state of cognitive functions, the regression of asthenia symptoms, and the improvement of night sleep. Differences were statistically significant in comparison with both the initial level and with the GS. Conclusion. The appointment of the drug does not require age -related dose correction and goes well with basic therapy. The recommended scheme for the use of Mexidol: 14 days for 5 ml of iv or/m, then taking the drug Mexol Forter 250 in a dose of 1 tablet 3 times a day for 2 months. Key words: chronic cerebrovascular diseases, post -shoe syndrome, Mexidol, treatment.